

PRESS RELEASE

Verdict confirms Collectis' fight to protect its intellectual property

Paris, November 12, 2009 – Collectis S.A. (Alternext: ALCLS), the French genome engineering specialist, has announced that the Paris *Tribunal de grande instance* has dismissed the lawsuit filed by Genoway in January 2009.

The third chamber of the *Tribunal de grande instance* returned today, Thursday, November 12, a verdict stating, among other things, that the contract between Collectis and Genoway was terminated on December 30th, 2008, that the under-license products detained by Genoway have to be destroyed, that the audit of Genoway's accounts has to be resumed and condemn Genoway to pay the sums they owed Collectis.

The verdict of the *Tribunal de grande instance*, dated November 12, 2009 is available on Collectis' website at: <http://www.collectis.com/en/news-events/>

About Collectis S.A.

[Collectis S.A.](#) is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Collectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and has over 20 collaborations with academic research groups. To date, Collectis has raised over €50 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Collectis, visit our website: www.collectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers ("AMF") granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

For further information, please contact:

Collectis SA
Sylvie Delassus
Senior VP Corporate Communication
+ 33 (0)1 41 83 99 00
media@collectis.com

Alize RP
Caroline Carmagnol
+33 (0) 6 64 18 99 59
caroline@alizerp.com